Cell News and Research

RSS

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

Research to study how eukaryotic cells help in building proteins

Federal stimulus funding is helping a Kansas State University biologist continue to collaborate with the Harvard Medical School. Their research is creating a clearer picture of a certain cellular process that can play a role in chronic diseases like cancer.

22 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Blood vessels around the brain now converted into production/delivery systems

The blood brain barrier is generally considered an obstacle to delivering therapies from the bloodstream to the brain. However, University of Iowa researchers have discovered a way to turn the blood vessels surrounding brain cells into a production and delivery system for getting therapeutic molecules directly into brain cells.

22 Sep 2009

UC professor argues on stem cell properties

Before it was learned that matter burns by taking up oxygen, most chemists sought to explain combustion as the release of a mysterious substance, which they named "phlogiston". Phlogiston theory was a conceptual breakthrough that helped chemists conduct experiments and share ideas. Only when it came to pinning down the distinctive physical properties of phlogiston did it become clear that no such thing exists.

22 Sep 2009

Cell Therapeutics announces that it has been added to the NASDAQ OMX Global Biotechnology Index

Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.

22 Sep 2009

Study on mice reveals that short term stress can prevent cancer

Researchers at the Stanford University School of Medicine have shown that, at least in laboratory mice, bouts of relatively short-term stress can boost the immune system and protect against one type of cancer. Furthermore, the beneficial effects of this occasional angst seem to last for weeks after the stressful situation has ended. The finding is surprising because chronic stress has the opposite effect -- taxing the immune system and increasing susceptibility to disease.

22 Sep 2009

Gene variant discovery could lead to future glaucoma treatments

An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Three-year results of SPIRIT III clinical trial reaffirms safety of PROMUS and TAXUS Express stents

Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS((R)) Express(2)(TM) Paclitaxel-Eluting Coronary Stent System and the XIENCE V(TM) (PROMUS((R))) Everolimus-Eluting Coronary Stent System.

22 Sep 2009

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.

22 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

Signaling molecules have different effects on key inhibitory protein

Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.

22 Sep 2009

Bacterium responsible for outbreaks identified

University of Central Florida Microbiology Professor Keith Ireton has uncovered a previously unknown mechanism that plays an important role in the spread of a deadly food-borne bacterium.

22 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.

21 Sep 2009

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

New data on signalling proteins, called G proteins, may prove important in fighting diseases such as cardiovascular, neurodegenerative disorders, and cancer. For many decades scientists have puzzled on "How signalling proteins transport and organize in specific areas of the cell?" Researchers from Nano-Science Center and Department of Neuroscience and Pharmacology at the University of Copenhagen provide yet unrecognized clues to solve this mystery.

21 Sep 2009

Cell News and Research

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Rexahn and Teva sign license and stock purchase agreements

Research to study how eukaryotic cells help in building proteins

Tregs to set the pace of recovery after serious lung injury

Blood vessels around the brain now converted into production/delivery systems

UC professor argues on stem cell properties

Cell Therapeutics announces that it has been added to the NASDAQ OMX Global Biotechnology Index

Study on mice reveals that short term stress can prevent cancer

Gene variant discovery could lead to future glaucoma treatments

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Three-year results of SPIRIT III clinical trial reaffirms safety of PROMUS and TAXUS Express stents

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Biochemists are developing a new system to better understand antibiotic resistance

Patients with higher levels of vitamin D are less likely to die from skin cancer

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Signaling molecules have different effects on key inhibitory protein

Bacterium responsible for outbreaks identified

Novel cleavage sites for enzyme caspase-3 identified

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News